Joseph E. Gilliam, the President and Chief Operating Officer of Glaukos Corp, has reported a transaction involving 986 shares of the company’s common stock. This transaction is significant as it highlights the ongoing management of executive stock holdings, a common practice among company leaders.

Glaukos Corp, a company based in Aliso Viejo, California, operates in the surgical and medical instruments and apparatus industry. The firm is known for its innovative approaches to treating eye diseases, particularly glaucoma. It trades under the ticker symbol GKOS.

According to the recent filing, Gilliam's transaction occurred on April 9, 2024. He acquired the shares at a price of $87.61 each. Following this transaction, Gilliam now holds a total of 71,602 shares, which includes 40,039 restricted stock units that have not yet vested or been delivered.

“Consists of shares withheld by the Issuer with respect to tax withholding obligations of the Reporting Person upon vesting and delivery of shares of common stock,” the filing stated.

This update may affect various stakeholders, including investors and employees, as it reflects Gilliam's confidence in the company’s performance and future prospects. The surgical and medical instruments industry may also see similar trends as executives navigate their equity stakes.

The filing does not say what happens next regarding Gilliam's holdings or any potential future transactions.